SCHEMBL4796808

SCHEMBL4796808

COc1ccc(NC[C@H](C)NC(=O)C(CC(C)C)NC(=O)c2cccc(C)c2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CTSS P25774 18/20 1.00
CTSL P07711 18/20 1.00
CTSK P43235 15/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4796814 1.00 CTSS (1.00) CTSSCTSLCTSK
SCHEMBL4802738 1.00 CTSS (1.00) CTSSCTSLCTSK
SCHEMBL4797519 1.00 CTSS (1.00) CTSSCTSLCTSK
SCHEMBL4800543 0.85 CTSL (0.75) CTSSCTSLCTSK
SCHEMBL4800528 0.85 CTSL (0.75) CTSSCTSLCTSK
SCHEMBL4801346 0.84 CTSS (0.71) CTSSCTSLCTSK
SCHEMBL4801339 0.84 CTSS (0.71) CTSSCTSLCTSK
SCHEMBL6687577 0.80 CTSL (0.72) CTSSCTSLCTSK
SCHEMBL4795899 0.78 CTSL (0.64) CTSSCTSLCTSK
SCHEMBL4795897 0.78 CTSL (0.64) CTSSCTSLCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242671-A1 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2008-10-02 US claimed
US-20080242671-A1 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2008-10-02 US disclosed
US-7384970-B2 Inhibitors of cathepsin S IRM LLC (BM) 2008-06-10 US disclosed
US-20040248887-A1 Inhibitors of cathepsin S IRM LLC (BM) 2004-12-09 US disclosed
WO-2004084843-A2 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2004-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248887-A1 Inhibitors of cathepsin S CTSS, CTSB, CTSZ CTSS 1/4885CTSL 11/4885CTSK 9/4885
US-20080242671-A1 INHIBITORS OF CATHEPSIN S CTSS, CTSB, CTSZ CTSS 1/4885CTSL 11/4885CTSK 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.